Presentado en CRT24: VELAZQUEZ Epic26 Study: IhtDEStiny® Coronary Stent

iEpic

VELAZQUEZ Epic26 Study: IhtDEStiny® Coronary Stent

Linares Vicente JA. De la Torre Hernández JM. Sainz Laso F. Casanova Sandoval JM. Rumoroso Cueva JR. Gómez Menchero A. Gómez Hospital JA. Tejedor Viñuela P. Fernández Portalés J. García Del Blanco B. Ocaranza Sánchez R. Urbano Carrillo C. Blanco Mata R. Vinhas H. Trillo Nouche R. García Blas S. Tellería Arrieta M. Torres Bosco A. Pinar Bermúdez E. Lozano Ruiz de Poveda F. Pérez de Prado A. on behalf of VELAZQUEZ Epic 26 investigators.

Prospective Registry:. 400 patients – 19 centers Spain and Portugal.

Primary End-Point

Target Lesion Failure (TLF) rate at 2 years; combined event:
• Cardiovascular death.
• Target vessel myocardial infarction.
• Clinically indicated target lesion revascularization.

Secondary End-Points

• Successfuldeviceimplantation:residualstenosis<30% & TIMI3 Flow without dissection ≥C at any implanted stent. • Procedural success: uneventful implantation or repeated revascularization within first 3 days. • Definite / probable stent thrombosis (ARC-2criteria). • BARC Bleeding rate(3-5). • Primary endpoint individual events.

CONCLUSIONS

In this real-world prospective registry, a new hydrodynamic ultrathin strut, sirolimus eluting- stent with durable polymer shows:
-High PCI success rate
-No acute stent thrombosis or early repeated revascularization
-Low Target Lesion Failure rate and no definite/probable stent thrombosis at mid-term follow up.

Download presentation.

Comparte este artículo: